MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX® (relugolix) in Canada. In June 2024, Knight and Sumitomo Pharma America Inc. (“SMPA”) announced that Knight and SMPA’s affiliates had entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well a ...

MINNEAPOLIS--(BUSINESS WIRE)--Agiliti, a leading manufacturer and provider of medical device solutions to the U.S. healthcare industry, has expanded its oncology offerings to physicians and hospitals, providing greater value and access to focal therapy services for diagnosing and treating prostate cancer. "There are approximately 313,000 new prostate cancer cases every year in the U.S., and innovative technologies like HIFU and other focal therapies are an important component of modern care,†e. ...

Core Message - The Depend campaign emphasizes the significance of early detection and emotional support for prostate cancer, with advocates encouraging open dialogue and screenings [1][2]. Group 1: Campaign and Advocacy - The Stand Strong for Men's Health™ campaign, launched in 2020, has donated over $1 million to the Prostate Cancer Foundation (PCF) to support critical research [2][6]. - Depend will donate up to $300,000 from select product sales to PCF during Prostate Cancer Awareness Month and Men's Health Awareness Month [2][7]. Group 2: Personal Stories and Impact - Griffey Jr. shares a personal connection to prostate cancer, highlighting that one in eight men will be diagnosed, and emphasizes the importance of early detection through simple blood tests [2][3]. - Smith stresses the need for open conversations about prostate cancer, particularly for Black men who face a 70% higher diagnosis rate [2][3]. Group 3: Research and Technological Advances - Research funded by PCF has led to advancements in prostate cancer evaluation and treatment, including the PSMA-PET scan, which improves early detection [3][6]. Group 4: Company Background - Kimberly-Clark, the parent company of Depend, operates in over 175 countries and is recognized for its sustainable practices and innovative products [5]. - The Prostate Cancer Foundation is a leading organization in funding prostate cancer research, having raised nearly one billion dollars since its inception [6].

Group 1 - The webinar series is hosted by Radiopharm, featuring discussions on advancements in prostate cancer treatment [1][2] - Dr. Oliver Sartor provided an overview of the prostate cancer treatment landscape, highlighting unmet medical needs and emerging therapies, including the combination of radium-223 with enzalutamide and targeted approaches like PSMA radiotherapeutics [2] - Pluvicto has significantly changed the prostate cancer treatment landscape, demonstrating efficacy in patients before and after chemotherapy, as evidenced by the PSMA 4 and VISION trials, and recently in hormone-sensitive prostate cancer through the PSMAddition trial [3] Group 2 - Despite advancements with PSMA-targeting treatments like Pluvicto, there remains a substantial medical need for new therapies as all patients receiving these treatments will eventually relapse [4]

Company Overview - Teleflex Incorporated (TFX) has launched the Barrigel rectal spacer in Japan, following regulatory approval and insurance coverage acceptance, marking a significant step in its global expansion strategy [1][8] - The Barrigel rectal spacer is the first hyaluronic rectal spacer designed to protect the rectum during radiation therapy for prostate cancer, made from Non-Animal Stabilized Hyaluronic Acid [4][5] Financial Performance - Following the Barrigel launch announcement, Teleflex's shares increased by 3.7%, closing at $124.30 [2][8] - Teleflex has a market capitalization of $5.55 billion and an earnings yield of 11.3%, which is favorable compared to the industry's -5.2% [3] Product Efficacy - A clinical study in the U.S. showed that 98% of men treated with the Barrigel rectal spacer achieved at least a 25% reduction in radiation exposure to the rectum, with an average reduction of 85% in rectal V54 Gy radiation [6] Industry Prospects - Japan's prostate cancer diagnostics market generated revenues of $345.5 million in 2023 and is projected to reach $438.0 million by 2030, with a CAGR of 3.4% from 2024 to 2030 [9] - Prostate cancer was the most common cancer among men in Japan in 2022, accounting for 18% of all cancer diagnoses [9] Recent Developments - Teleflex completed the acquisition of the majority of BIOTRONIK SE & Co. KG's Vascular Intervention business for €760 million, enhancing its interventional access product line and global presence [10]

Financial Data and Key Metrics Changes - For Q2 2025, the company received total orders of over $3 million and recorded revenue of $2.2 million, with $1.6 million from recurring revenue and $650,000 from one-time capital equipment sales [6][7] - Gross margin in Q2 2025 was 73%, up from 64% in Q2 2024 [6] - Total operating expenses in Q2 2025 were $15.4 million, compared to $9.3 million in Q2 2024 [6] - The net loss for Q2 2025 was $15.7 million, or $0.52 per share, compared to a net loss of $6.9 million, or $0.28 per share, in Q2 2024 [7] Business Line Data and Key Metrics Changes - The company is transitioning from a placement model to a capital model, which is expected to lead to a backend-loaded revenue operation [8][9] - The sales pipeline includes close to 500 prospects, with over 100 leads engaged and 80 qualified leads in the verification, negotiation, and contracting stages [10][11] Market Data and Key Metrics Changes - The U.S. sales team has been streamlined to focus on organizational sales to corporatized hospitals, emphasizing the importance of intangible attributes like grit and perseverance in sales success [12][13] - The company aims to increase the number of active sites in the U.S., with a target of at least 75 by the end of the year [61] Company Strategy and Development Direction - The CAPTAIN trial has been fully recruited, which is expected to drive adoption of the TULSA procedure and influence treatment guidelines [15][16] - The pilot release of the new TULSA AI volume reduction software is anticipated to enhance efficiency in BPH procedures, moving TULSA from a niche to a mainstream treatment option [19][20] - The company is optimistic about the integration of TULSA with new interventional MR technologies, which could enhance its market position [63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 70% to 75% revenue growth in 2025 compared to 2024, despite short-term revenue shortfalls due to delays in capital sales [8][22] - Positive feedback from physicians regarding the CAPTAIN trial completion is expected to enhance adoption and pipeline growth [36][37] - The company anticipates that as more data is published, it will lead to new guidelines requiring that TULSA be presented as a treatment option alongside traditional methods [23] Other Important Information - The company has approximately $35.2 million in cash as of June 30, 2025 [7] - The initial clinical outcomes from the CAPTAIN trial are expected to be presented at major medical meetings in December [19][94] Q&A Session Summary Question: Can you provide insights on the sales contribution from recurring and capital perspectives? - Management indicated that the revenue mix is expected to shift from recurring to capital revenue as the installed base grows, with a long-term goal of 70% recurring and 30% capital revenue [29][30] Question: What feedback are you receiving from physicians regarding the CAPTAIN trial? - High positive feedback has been received, particularly regarding the completion of the trial, which is seen as a significant achievement in the field [36][37] Question: How does the proposed reimbursement rule for BPH treatments affect TULSA? - The company maintained favorable reimbursement levels compared to other BPH procedures, which positions TULSA advantageously in the market [44][45] Question: What is the current number of active TULSA placements in the U.S.? - There are about 60 active sites, with plans to install three more, aiming for at least 75 by year-end [61] Question: How is the soft launch of the volume reduction module for BPH going? - Initial feedback has been excellent, with procedure times averaging closer to 60 minutes, which is a significant improvement [90][91]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Insights - CEO.CA is a leading investor social network focused on junior resource and venture stocks, providing exclusive updates to CEOs of junior mining explorers [1][6] - The platform has gained popularity since its founding in 2012, attracting millions of global investors to discuss stocks, commodities, and emerging companies [2][6] - The "Inside the Boardroom" series offers insights from industry leaders, enhancing understanding of their vision and strategies [3][4] Company Highlights - Dr. John Yu, CEO of Kairos Pharma, discussed the company's prostate cancer trial, which reported zero grade 3 or 4 toxicities, a significant improvement compared to over 50% with standard treatments [4] - The upcoming efficacy data in September and plans for expansion into lung cancer and other tumor types were also highlighted [4][8] - CEO.CA serves as a platform for showcasing companies and connecting with investors, emphasizing its role in the investment community [5][6]

Core Insights - The European Commission has granted marketing authorization for darolutamide, an oral androgen receptor inhibitor, in combination with androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer [2][8] - The approval is based on the positive results from the Phase III ARANOTE trial, which demonstrated a 46% reduction in the risk of radiological progression or death compared to placebo [2][7] Company Overview - Darolutamide, marketed as Nubeqa®, is developed jointly by Orion and Bayer and is already approved in over 85 countries for various indications related to prostate cancer [3][8] - Orion Corporation is a Nordic pharmaceutical company with a focus on oncology and pain management, employing approximately 3,700 professionals and generating net sales of EUR 1,542 million in 2024 [15][17] Industry Context - Prostate cancer is the second most common cancer among men globally, with an estimated 1.5 million new cases diagnosed in 2022 and projected to rise to 2.9 million by 2040 [4] - The ARANOTE trial involved 669 patients and aimed to assess the efficacy and safety of darolutamide plus ADT, with the primary endpoint being radiological progression-free survival [5][6]

Core Insights - Novartis anticipates Kisqali to become a blockbuster drug, shifting focus from Entresto [1] - Kisqali sales increased by 64% globally in Q2, with 100% growth in the U.S. [1] - The company reported a 56% increase in Kisqali sales in Q1 [2] Industry Trends - Global breast cancer diagnoses and deaths are expected to rise significantly by 2050, with 1 in 20 women projected to be diagnosed [2] - This could lead to 3.2 million new cases and 1.1 million deaths annually by 2050, compared to 2.3 million new cases and 670,000 deaths in 2022 [3] Company Pipeline - Novartis has a strong pipeline with other potential blockbusters like Pluvicto for prostate cancer and Scemblix for chronic myeloid leukemia [3] - The company is focused on driving performance for Kisqali, Pluvicto, and Scemblix, indicating a strategy to replace reliance on older therapies [3]